XKRX228760
Market cap258mUSD
Aug 14, Last price
17,200.00KRW
Name
Genomictree Inc
Chart & Performance
P/E
—
P/S
110.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.72%
Rev. gr., 5y
54.61%
Revenues
3.42b
-88.56%
Net income
-8.76b
L+40.38%
CFO
-10.88b
L
Profile
Genomictree Inc is a molecular diagnostic company. It is engaged in developing technologies that satisfies the unmet needs of the healthcare market.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 3,418,009 -88.56% | 29,865,675 481.09% | 5,139,615 314.87% | ||||||
Cost of revenue | 10,948,484 | 19,357,893 | 8,765,334 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (7,530,474) | 10,507,782 | (3,625,719) | ||||||
NOPBT Margin | 35.18% | ||||||||
Operating Taxes | (496,609) | 2,544,034 | 916 | ||||||
Tax Rate | 24.21% | ||||||||
NOPAT | (7,033,866) | 7,963,747 | (3,626,635) | ||||||
Net income | (8,756,037) 40.38% | (6,237,388) -45.40% | (11,424,524) -2.55% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (4,984,398) | 4,996,167 | |||||||
BB yield | 2.70% | -1.82% | |||||||
| Debt | |||||||||
Debt current | 1,737,143 | 29,095,310 | 265,790 | ||||||
Long-term debt | (2,097,966) | 222,047 | 39,351,990 | ||||||
Deferred revenue | 2,340,415 | 21,523,160 | |||||||
Other long-term liabilities | 10 | 1,246,541 | (10) | ||||||
Net debt | (59,678,386) | (59,390,832) | (46,499,541) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (10,880,530) | 4,285,629 | (7,630,666) | ||||||
CAPEX | (288,399) | (1,824,121) | (11,827,864) | ||||||
Cash from investing activities | 8,119,075 | 14,069,030 | (49,071,782) | ||||||
Cash from financing activities | (20,496,868) | (19,524,691) | 62,868,642 | ||||||
FCF | (6,627,040) | 13,475,592 | (16,371,490) | ||||||
| Balance | |||||||||
Cash | 93,146,379 | 114,605,125 | 130,531,225 | ||||||
Long term investments | (33,828,817) | (25,896,935) | (44,413,904) | ||||||
Excess cash | 59,146,662 | 87,214,906 | 85,860,340 | ||||||
Stockholders' equity | 43,575,770 | 51,146,473 | 56,985,740 | ||||||
Invested Capital | 85,335,605 | 86,835,337 | 118,082,691 | ||||||
ROIC | 7.77% | ||||||||
ROCE | 7.58% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 21,764 | 20,984 | 20,659 | ||||||
Price | 8,790.00 -33.91% | 13,300.00 -9.22% | |||||||
Market cap | 184,445,897 -32.87% | 274,767,041 -6.18% | |||||||
EV | 125,712,381 | 228,655,096 | |||||||
EBITDA | (6,352,454) | 11,842,907 | (2,603,471) | ||||||
EV/EBITDA | 10.61 | ||||||||
Interest | 2,054,342 | 5,382,239 | 4,605,542 | ||||||
Interest/NOPBT | 51.22% | ||||||||